A South Korean court ruled in favor of the generic companies in an appeal case for a patent dispute on an antidiabetic sodium-glucose co-transporter-2 (SGLT2) inhibitor Forxiga (dapagliflozin). The original company AstraZeneca lost another patent litigation in a higher court after losing from the Intellectual Property Trial and Appeal Board’s case.

On Oct. 29, the Patent Court has rejected AstraZeneca’s appeal filed in last May to undo the preceding Intellectual Property Trial and Appeal Board’s decision ruled for 19 pharmaceutical companies with the generics.

Regardless, the generic companies again won the five-month-long appeal case. The following companies participated in the cas